Canine Adenovirus Type 2, Strain Manhattan, 12-13-76;Canine Distemper Virus, Str

Verify with FDA CVM →

454 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
454
Total Reports
47
Deaths Reported
1040.0%
Death Rate

Active Ingredients

Canine Adenovirus Type 2, Strain Manhattan, 12-13-76;Canine Distemper Virus, Str

Administration Routes

SubcutaneousUnknownOral

Species Affected

Dog 454

Most Affected Breeds

Chihuahua 32
Retriever - Golden 32
Retriever - Labrador 30
Dachshund (unspecified) 22
Terrier - Bull - American Pit 21
Crossbred Canine/dog 21
Schnauzer - Miniature 17
Bulldog - French 15
Boxer (German Boxer) 14
Terrier (unspecified) 14

Most Reported Reactions

Vomiting 157
Lethargy (see also Central nervous system depression in Neurological) 103
Facial swelling (see also Skin) 75
Anaphylaxis 60
Diarrhoea 52
Pale mucous membrane 45
Not eating 43
Hives (see also Skin) 43
Seizure NOS 34
Fever 33
Emesis (multiple) 33
Death 30

Outcome Breakdown

Ongoing
241 (53.1%)
Recovered/Normal
137 (30.2%)
Died
32 (7.0%)
Outcome Unknown
29 (6.4%)
Euthanized
15 (3.3%)

Data Summary

Metric Value
Total adverse event reports 454
Reports involving death 47
Case-fatality rate (reported events) 1040.0%
Distinct species in reports 1
Distinct breeds in reports 20
Distinct reactions reported 20
Active ingredients on file 1

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Canine Adenovirus Type 2, Strain Manhattan, 12-13-76;Canine Distemper Virus, Str Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 454 adverse event reports referencing Canine Adenovirus Type 2, Strain Manhattan, 12-13-76;Canine Distemper Virus, Str, including 47 reports in which the animal died — a 1040.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredient on file: Canine Adenovirus Type 2, Strain Manhattan, 12-13-76;Canine Distemper Virus, Str. Reported administration routes include Subcutaneous, Unknown, Oral. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Canine Adenovirus Type 2, Strain Manhattan, 12-13-76;Canine Distemper Virus, Str reports are Dog (454 reports), with Dog accounting for the largest share. Within those species, Chihuahua (32), Retriever - Golden (32), Retriever - Labrador (30) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Canine Adenovirus Type 2, Strain Manhattan, 12-13-76;Canine Distemper Virus, Str are Vomiting (157), Lethargy (see also Central nervous system depression in Neurological) (103), Facial swelling (see also Skin) (75), Anaphylaxis (60). Of the 454 reports with a coded outcome, Ongoing is the leading category at 53.1%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Canine Adenovirus Type 2, Strain Manhattan, 12-13-76;Canine Distemper Virus, Str.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial